From a clinical perspective, a bispecific tracer could prove most valuable in lesions with heterogeneous marker expression—where GPC3 is low in some niches but PSMA remains high in neovasculature, or vice versa—thus maximizing detection sensitivity across diverse tumor phenotypes. This evidence concerns the gene GPC3 and neoplasm.